Technology licensing and industry partnerships

The Office of Strategic Alliances and Partnering (OSAP) works with pharmaceutical, biotech, and technology companies, as well as investors to license ӳ��ý intellectual property, create new companies, and collaborate on research — all to help our partners discover, develop, and commercialize human health products based on ӳ��ý science and technology.

OSAP is the business development and licensing engine of the ӳ��ý and welcomes opportunities to explore new partnerships and ventures with industry. Our goal is to close the gap between discoveries at ӳ��ý and benefits for patients through close collaborations and licensing agreements with industry partners.

ӳ��ý’s unique institutional structure enables partnerships that span multiple investigators and scalable platform technologies across a variety of research areas.

Please contact us at partnering@broadinstitute.org

Technology licensing and new ventures

Here are a few examples of how ӳ��ý has successfully partnered with industry to drive impact in human health and research:

► Therapeutics companies ► Delivery companies ► Technology companies ► Gene editing non-exclusive licensing ► Software

These clinical-stage companies were founded with exclusive licenses to ӳ��ý-developed gene editing technologies for therapeutic applications:

Beam Therapeutics: testing several base-editing treatments in clinical trials for genetic diseases
Editas Medicine: testing CRISPR-Cas9/Cas12a-based treatments. Editas has exclusive licences to these CRISPR technologies from ӳ��ý for human medicines, which enabled Casgevy, the first FDA-approved CRISPR medicine.
Prime Medicine: testing several prime editors in preclinical work and an early-stage clinical trial for genetic diseases and cancer

A conceptual 3D illustration of prime editing, showing a molecular machine (Cas9 and reverse transcriptase) interacting with a DNA double helix to 'search and replace' a specific genetic sequence.

These companies launched with licensing agreements with ӳ��ý to build new approaches to delivering genetic medicines to targeted cells and tissues in the body:

Aera Therapeutics: a delivery-focused genetic medicine company focusing on nanoparticles and other approaches
Apertura Gene Therapy: advancing AAVs for genetic medicines for central nervous system and neuromuscular diseases
Kate Therapeutics: developing AAV-based genetic medicines for neuromuscular disorders. .

Here are examples of companies that are commercializing research technologies developed at ӳ��ý, scaling them up and lowering costs to help advance science everywhere.

Bifrost Biosystems signed an exclusive licensing agreement with ӳ��ý in 2024 to gain access to optical pooled screening, a ӳ��ý-developed technology that connects single-cell phenotype to genotype at massive scale.

Curio Bioscience launched in 2023 to commercialize high-resolution and single-cell spatial mapping tools developed at ӳ��ý. .

In situ sequencing identifies the gene knockout in each cell of a pooled CRISPR library. Fluorescence microscopy records both cellular phenotypes and sequencing data (cell nuclei are depicted in gray and the nucleotide bases are green = guanine, red = thymine, magenta = adenine and cyan = cytosine).

ӳ��ý grants non-exclusive licenses to gene editing technologies for academic/research and agricultural use. Learn more here.

Conceptual illustration of CRISPR-Cas9 system by Stephen Dixon.

ӳ��ý partnered with Manifold, a leader in research infrastructure for biomedical science, to develop a cutting-edge research platform. The platform builds on the principles of , a trusted system for large-scale data analysis and secure collaboration.

ӳ��ý also collaborated with Illumina to for genomic data analysis.

Research collaborations

Through longstanding partnerships, ӳ��ý and industry scientists work closely together to make new discoveries and move them toward clinical application. Some examples of our strategic research collaborations include:

► Bayer Healthcare Pharmaceuticals ► Calico Life Sciences ► Jaguar Gene Therapy ► Microsoft ► Industry Consortia

ӳ��ý-Bayer alliances launched in 2013 for oncology and in 2015 for cardiovascular research. The oncology alliance has led to a lung cancer drug, Hyrnuo®, which received FDA accelerated approval in 2025. The cardiovascular partnership has resulted in an atrial fibrillation drug candidate in early-stage clinical testing.

ӳ��ý and Calico began their partnership in 2015 focused on diseases of aging. It has resulted in a cancer immunotherapy candidate .

Protein diagram showing the new small molecule inhibitor nestled inside the PTPN2 protein.

In 2017, ӳ��ý and Deerfield Management began a partnership focused on early-stage academic and therapeutics research. In 2019, , including JAG201 for a leading monogenic cause of autism, which is clinically diagnosed as Phelan-McDermid syndrome and is caused by pathogenic variants in the SHANK3 gene or from chromosome 22q13.3 deletions encompassing SHANK3. . JAG201 is currently in an early-stage .

Scientific illustration of the Shank3 protein and its role in genetic brain disorders.

A joint cancer research collaboration between and called Project Ex Vivo envisions a new, constructionist paradigm for precision oncology, one powered by the bottom-up integration of experimentation and computation.

ӳ��ý leads or is a key partner in cutting-edge consortia with industry collaborators, including the , which launched in 2018 and has 22 biopharma partners.

Photo of Todd Golub

Industry partnerships are essential for translating ӳ��ý’s fundamental discoveries into applications that directly benefit patients as well as our partners. Today, more than 15 therapeutic programs are in clinical trials and two have received FDA approval through our licensees, sublicensees, and strategic partners. This long history of working with industry demonstrates the strength and effectiveness of our partnership model.

Michael Christiano, Chief Business Officer, ӳ��ý

photo of Michael Christiano